<DOC>
	<DOCNO>NCT03083054</DOCNO>
	<brief_summary>The main objective work conduct clinical study development application vaccine autologous dendritic cell submit electroporation Wilm 's tumor 1 ( WT1 ) messenger ribonucleic acid ( mRNA ) , adjuvant treatment high-risk Myelodysplastic Syndromes Acute Myeloid Leukemia , aim delay progression disease relapse increase overall event-free survival .</brief_summary>
	<brief_title>Cellular Immunotherapy Patients With High Risk Myelodysplastic Syndromes Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Individuals age 18 70 Highrisk myelodysplasia ( AREB 1 AREB 2 subtypes ) Acute Myeloid Leukemia Minimum interval 30 day last cycle chemotherapy ( occurs ) start immunotherapy Performance status 0 3 WHO ( World Health Organization ) ECOG ( Eastern Cooperative Oncology Group ) scale Calculated creatinine clearance &gt; 30 ml / min use CockcroftGault formula Total bilirubin less equal twice lower limit normal range institution aspartate aminotransferase ( AST ) less equal twice upper limit normal Absence blast peripheral blood Leukocyte count great 3000 cell / mm3 , hemoglobin great 9.0 g / dl platelet great 70,000 platelet / mm3 , possible . ( If patient meet criterion apheresis , possibility transfusion blood component leukapheresis propose patient sign specific term science possibility transfusion ) Normal cardiac evaluation Negative serology hepatitis B C viruses HIV Written inform consent form sign enter study Does meet requirement inclusion criterion Low risk myelodysplasia IPSS ( International Prognostic Scoring System ) WPSS ( WHO adapt Prognostic Scoring System ) score Individuals history previous neoplasia , except prolonged clinical remission ( 5 year ) nonmelanoma skin cancer cervical cancer situ Pregnant lactate woman Previous immunotherapy biological therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>